ToolGen (199800) Fundamentals 2026 — Revenue Analysis | SniperIQ
ToolGen (199800) is a KR-listed Healthcare company in Medical - Specialties with a market capitalization of ₩335.5B, trading at ₩37300.00 on the KOE. This SniperIQ fundamentals page covers ToolGen's valuation, profitability (net margin -2342.7%), revenue (₩1.3B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is ToolGen's market cap?
ToolGen (199800) has a market capitalization of approximately ₩335.5B, trading at ₩37300.00 on the KOE. Market cap moves with the live share price.
What is ToolGen's P/E ratio?
ToolGen's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 6.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is ToolGen?
ToolGen runs a net profit margin of -2342.7%, a gross margin of -46.9%, and an operating margin of -1486.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does ToolGen generate?
ToolGen reported revenue of ₩1.3B for fiscal year 2025, with net income of -₩36.8B and earnings per share (EPS) of -4099.41. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does ToolGen pay a dividend?
ToolGen does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is ToolGen financially healthy?
ToolGen carries a debt-to-equity ratio of 0.00x and a current ratio of 10.94x, with a market beta of 1.24. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is ToolGen a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For ToolGen (199800) the key facts are: market cap ₩335.5B, revenue ₩1.3B, 52-week range 26650-142000. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track ToolGen's full fundamentals live
Get ToolGen's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.